-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
November 2024
-
Combining Inflammatory Pathway Modulators and Immune Cell Activators with Immunotherapy May Improve or Rescue Responsiveness
Experts, including Dr. Melina E. Marmarelis, revealed different approaches to overcoming resistance to immune checkpoint inhibitors.
-
Breakthroughs in Targeting KRAS G12C Mutations in NSCLC
Dr. Ziming Li and other panelists recently explored encouraging clinical trial data for novel therapies, including garsorasib, olomorasib, fulzerasib, and divarasib.
-
Study Demonstrates Multidisciplinary Approach Can Improve Care for Elderly Lung Cancer Patients
During the 2024 WCLC, Dr. Shalini Vinod reviewed data showing that a nurse-led care model for geriatric patients outperformed a medical-led model.
-
Taletrectinib Shows Promising Results in Patients with ROS1-Positive NSCLC
Dr. Geoffrey Liu presented results from the TRUST-II trial on the safety and efficacy of taletrectinib in TKI-naive and TKI-pretreated patients.
-
The Art of Science Communications
IASLC Communications Committee members gathered during a WCLC 2024 workshop to share tips on tailoring messages to different audiences, building a strong social media presence, and more.
-
WCLC Closing Plenary Explored Overcoming Barriers to Patient Advocacy Worldwide
Global leaders in patient advocacy assembled during the 2024 World Conference on Lung Cancer to shed light on ongoing initiatives.
-
Data Link Air Pollution Exposure to Oncogene-Driven Lung Cancer Diagnoses
Dr. Yixian Crystal Chen recently presented results that demonstrate fine particulate matter poses health risks, even for those with no smoking history.
-
Study Evaluating Tusamitamab Ravtansine in Patients with Non-Squamous NSCLC is Discontinued
Dr. Benjamin Besse recently discussed detailed findings from the now discontinued CARMEN-LC03 trial.
-
LUMINOSITY Subgroup Analysis Shows Similar Results for Asian Patients Compared to Global Population
Dr. Hidehito Horinouchi said treatment with Teliso-V demonstrated promising and durable responses in Asian cohort, particularly those with high c-Met expression.
-
TROPION-Lung01 Demonstrates Improvement in PFS; OS Improvement Fails to Reach Statistical Significance
Dr. Jacob Sands presented findings that show a progression-free survival advantage for Dato-DXd versus docetaxel in the non-squamous cohort.